- Venetoclax - Wikipedia
Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML)
- Venetoclax: Uses, Dosage, Side Effects, Warnings - Drugs. com
Venetoclax (brand name Venclexta) may be used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults, or newly diagnosed acute myeloid leukemia (AML) in those aged 75 years or older, or with other conditions that prevent intensive chemotherapy
- Venetoclax - NCI - National Cancer Institute
Venetoclax is approved to treat: Acute myeloid leukemia that is newly diagnosed It is used in adults aged 75 years and older or adults who cannot be treated with intensive induction chemotherapy It is given with either azacitidine, decitabine, or low-dose cytarabine
- Venetoclax (oral route) - Mayo Clinic
Venetoclax is used alone or together with other medicines (eg, rituximab) to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, in patients who have received at least one previous treatment
- venetoclax (Rx) - Medscape Drugs Diseases
Indicated in combination with azacitidine or decitabine or low-dose cytarabine for treatment in adults (≥75 years) who are newly-diagnosed acute myeloid leukemia (AML) or who have comorbidities
- Venetoclax - Chemocare
VENETOCLAX (ven ET oh klax) treats leukemia and lymphoma It works by blocking a protein that causes cancer cells to grow and multiply This helps to slow or stop the spread of cancer cells
- Venclexta (venetoclax) - Uses, Side Effects, and More
Find patient medical information for Venclexta (venetoclax) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
- Venetoclax (Venclexta) Tablets - FDA
On April 11, 2016, the U S Food and Drug Administration approved venetoclax (VENCLEXTA tablets, marketed by AbbVie, Inc and Genentech USA, Inc ) for the treatment of patients with chronic
|